 |
Telmisartan Market |
The availability of better hypertension treatment choices has resulted in a significant majority of the hypertensive population having their blood pressure under control.
However, the growing global population with cardiovascular and related illnesses necessitates the development of new antihypertensive medications.
Telmisartan market is a non-peptide angiotensin-converting enzyme inhibitor used to treat hypertension and other cardiovascular problems.
The US Food and Drug Administration (USFDA) approved telmisartan for the treatment of hypertension in 1998, either alone or in combination with other drugs.
The global telmisartan market was worth US$ 3,880.9 million in 2017, and it is predicted to grow at a CAGR of 1.4 percent between 2018 and 2026.
The Telmisartan market is predicted to develop due to an increase in government programs aimed at raising awareness about cardiovascular and blood pressure issues.
The Texas Council on Cardiovascular Disease and Stroke collaborate with key stakeholders to put a plan in place to reduce the burden of cardiovascular disease and stroke in Texas.
The plan includes a snapshot of the current state of cardiovascular disease and stroke in Texas, a summary of findings from the heart disease and stroke preventive system assessment, and data on mortality, morbidity, prevalence, and risk factors.
Globally increasing hypertension prevalence is increasing the illness burden and driving demand for antihypertensive medications in the global market.
For example, between 1960 and 2014, the National Health and Nutrition Examination Surveys (NHANES) provided important epidemiologic information on the prevalence and control of hypertension in the United States, revealing that 26% of the world's adult population (972 million) had hypertension in 2000, with the number increasing by 31% (1.39 billion) in 2010, and the number expected to reach 1.56 billion by 2025.
The market for Telmisartan: A Competitive Analysis
Medtronic Plc., General Electric Company, C. R. Bard, Inc., and ConvaTec Group plc. are some of the major participants in the Telmisartan industry.
Smith Medical, Inc., KindWell Medical Equipment Co., Ltd., Royal, Fuji Systems Corp., Teleflex Incorporated., Neurovision Medical Products, and Intersurgical GmbH are among the companies that make medical equipment.
However, the growing global population with cardiovascular and related illnesses necessitates the development of new antihypertensive medications.
Telmisartan market is a non-peptide angiotensin-converting enzyme inhibitor used to treat hypertension and other cardiovascular problems.
The US Food and Drug Administration (USFDA) approved telmisartan for the treatment of hypertension in 1998, either alone or in combination with other drugs.
The global telmisartan market was worth US$ 3,880.9 million in 2017, and it is predicted to grow at a CAGR of 1.4 percent between 2018 and 2026.
The Telmisartan market is predicted to develop due to an increase in government programs aimed at raising awareness about cardiovascular and blood pressure issues.
The Texas Council on Cardiovascular Disease and Stroke collaborate with key stakeholders to put a plan in place to reduce the burden of cardiovascular disease and stroke in Texas.
The plan includes a snapshot of the current state of cardiovascular disease and stroke in Texas, a summary of findings from the heart disease and stroke preventive system assessment, and data on mortality, morbidity, prevalence, and risk factors.
Globally increasing hypertension prevalence is increasing the illness burden and driving demand for antihypertensive medications in the global market.
For example, between 1960 and 2014, the National Health and Nutrition Examination Surveys (NHANES) provided important epidemiologic information on the prevalence and control of hypertension in the United States, revealing that 26% of the world's adult population (972 million) had hypertension in 2000, with the number increasing by 31% (1.39 billion) in 2010, and the number expected to reach 1.56 billion by 2025.
The market for Telmisartan: A Competitive Analysis
Medtronic Plc., General Electric Company, C. R. Bard, Inc., and ConvaTec Group plc. are some of the major participants in the Telmisartan industry.
Smith Medical, Inc., KindWell Medical Equipment Co., Ltd., Royal, Fuji Systems Corp., Teleflex Incorporated., Neurovision Medical Products, and Intersurgical GmbH are among the companies that make medical equipment.
0 Comments